GnRH antagonist peptide analog
Cetrorelix
Cetrorelix is a peptide GnRH antagonist. Its research examines how one receptor relates to several intracellular signals. Similarity to other family antagonists does not imply identical results in every assay.
This is a research reference, not a product offered in the Asciende catalog. Published studies do not establish the identity, purity or availability of a commercial preparation.
Hormonal axis, time and response type
Record time and model as well as name. A class label alone does not predict every response of a feedback system.
- Is the entity described as an agonist, antagonist or modulator in the cited assay?
- Are immediate response and adaptation after a different exposure distinguished?
- Is the biomarker a direct receptor readout or a consequence of the whole axis?
Mechanism described in the literature
In vitro, cetrorelix inhibits GnRH-evoked responses. Comparison with ganirelix and teverelix showed that compound differences depend on the measured pathway and cellular system.
Other names in the literature
- Cetrorelix
Several signals for one target
A 2019 study combined cells with experimentally introduced receptor and mouse pituitary cells. It examined calcium, cyclic AMP, signaling proteins and Lhb transcription. Cetrorelix differed from other antagonists in some in vitro responses but not equally across all readouts.
A model outside the pituitary
Another investigation used the BPH-1 prostate cell line. Cetrorelix was associated with lower proliferation and changes in growth-factor receptors and signaling in vitro. This addressed local culture responses rather than a complete endocrine circuit.
Potency depends on what is counted
An antagonist comparison may change between a rapid signal and a gene-expression response. A receptor introduced into a cell line is not interchangeable with native expression in another tissue. Target name alone is insufficient to rank compounds.
Questions and answers
Are cetrorelix and ganirelix equivalent in every assay?
No. The comparison found differences in some in vitro signals and similarities in others.
Does a BPH-1 response prove a general endocrine effect?
No. It describes a prostate cell model with local variables, not the entire hormonal axis.
Sources
- GnRH Antagonists Produce Differential Modulation of the Signaling Pathways Mediated by GnRH Receptors. — Int J Mol Sci, 2019
- GnRH Antagonists Produce Differential Modulation of the Signaling Pathways Mediated by GnRH Receptors.
- Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. — BJU Int, 2010
- Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix.